Transações de insiders

EDGAR

Evoke Pharma Inc

Transações informadas por diretores, executivos e detentores de mais de 10 % nos Formulários 3, 4 e 5 da SEC, lidas do XML de cada documento. Os códigos e sua redação são os da SEC.

O Formulário 4 deve ser entregue em até dois dias úteis após a transação; as mais recentes podem ainda não ter sido registradas.

Janela: transações datadas de 16 de nov. de 2025 em diante.

Compras no mercado aberto (código P)
0 transações, — ações
Vendas no mercado aberto (código S)
0 transações, — ações

Os totais somam as transações listadas; contam o que foi informado e não medem uma direção.

Exibindo 1–37 de 37

Transações de insiders, mais recentes primeiro, conforme os Formulários 3, 4 e 5 da SEC
DataDeclaranteCódigoAdquirido ou alienadoAçõesPreço por ação, conforme entregueValor (derivado)Ações detidas depoisDireta ou indiretaCaixa da Regra 10b5-1NotasFonte
17 de dez. de 2025 Protocolado em 19 de dez. de 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Alienado (D)148.15311,00
1.629.683

Derivado: ações × preço por ação. Valor exato 1629683.00.

0Indireta (I) See FootnoteNão
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir documento 0001104659-25-123156 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 19 de dez. de 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor mobiliário derivativo: Prefunded Warrants — subjacente Common Stock (433.962) — preço de exercício 0.0001
Alienado (D)433.96210,999
4.773.148,038

Derivado: ações × preço por ação. Valor exato 4773148.038.

0Indireta (I) See FootnoteNão
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir documento 0001104659-25-123156 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 19 de dez. de 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor mobiliário derivativo: Series A Common Stock Purchase Warrants — subjacente Common Stock (117.019) — preço de exercício 8.16
Alienado (D)117.0194,71
551.159,49

Derivado: ações × preço por ação. Valor exato 551159.49.

0Indireta (I) See FootnoteNão
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir documento 0001104659-25-123156 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 19 de dez. de 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor mobiliário derivativo: Series C Common Stock Purchase Warrants — subjacente Common Stock (117.019) — preço de exercício 8.16
Alienado (D)117.0194,71
551.159,49

Derivado: ações × preço por ação. Valor exato 551159.49.

0Indireta (I) See FootnoteNão
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir documento 0001104659-25-123156 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 19 de dez. de 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor mobiliário derivativo: Amended Series A Common Stock Purchase Warrants — subjacente Common Stock (158.531) — preço de exercício 0.01
Alienado (D)158.53110,99
1.742.255,69

Derivado: ações × preço por ação. Valor exato 1742255.69.

0Indireta (I) See FootnoteNão
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir documento 0001104659-25-123156 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 19 de dez. de 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Valor mobiliário derivativo: Amended Series C Common Stock Purchase Warrants — subjacente Common Stock (250.627) — preço de exercício 0.01
Alienado (D)250.62710,99
2.754.390,73

Derivado: ações × preço por ação. Valor exato 2754390.73.

0Indireta (I) See FootnoteNão
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
Abrir documento 0001104659-25-123156 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.218) — preço de exercício 5.41
Alienado (D)1.218——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322642 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (5.833) — preço de exercício 4.45
Alienado (D)5.833——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322642 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.218) — preço de exercício 3.453
Alienado (D)1.218——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322642 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.479) — preço de exercício 5.41
Alienado (D)1.479——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322643 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (8.750) — preço de exercício 4.45
Alienado (D)8.750——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322643 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.291) — preço de exercício 3.453
Alienado (D)1.291——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322643 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.187) — preço de exercício 5.41
Alienado (D)1.187——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322641 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (5.833) — preço de exercício 4.45
Alienado (D)5.833——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322641 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.187) — preço de exercício 3.453
Alienado (D)1.187——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322641 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.250) — preço de exercício 5.41
Alienado (D)1.250——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322638 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (5.833) — preço de exercício 4.45
Alienado (D)5.833——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322638 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.250) — preço de exercício 3.453
Alienado (D)1.250——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322638 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.218) — preço de exercício 5.41
Alienado (D)1.218——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322639 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (5.833) — preço de exercício 4.45
Alienado (D)5.833——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322639 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.187) — preço de exercício 3.453
Alienado (D)1.187——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322639 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (5.833) — preço de exercício 5.51
Alienado (D)5.833——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322645 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.125) — preço de exercício 3.453
Alienado (D)1.125——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322645 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (17.291) — preço de exercício 5.27
Alienado (D)17.291——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322644 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (11.000) — preço de exercício 4.45
Alienado (D)11.000——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322644 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (64.840) — preço de exercício 5.27
Alienado (D)64.840——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322637 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (70.000) — preço de exercício 4.45
Alienado (D)70.000——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322637 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (17.291) — preço de exercício 5.27
Alienado (D)17.291——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322640 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (13.000) — preço de exercício 4.45
Alienado (D)13.000——0Direta (D) Não
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322640 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (5.833) — preço de exercício 5.26
Alienado (D)5.833——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322646 Lido do XML do documento Contestar esta linha
17 de dez. de 2025 Protocolado em 17 de dez. de 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Valor mobiliário derivativo: Stock Option (Right to Buy) — subjacente Common Stock (1.155) — preço de exercício 3.453
Alienado (D)1.155——0Direta (D) Não
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Abrir documento 0001193125-25-322646 Lido do XML do documento Contestar esta linha
16 de dez. de 2025 Protocolado em 17 de dez. de 2025Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Alienado (D)133——0Direta (D) Não
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir documento 0001193125-25-322642 Lido do XML do documento Contestar esta linha
16 de dez. de 2025 Protocolado em 17 de dez. de 2025GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Alienado (D)2.330——0Indireta (I) By Garner Investments, L.L.C.Não
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir documento 0001193125-25-322643 Lido do XML do documento Contestar esta linha
16 de dez. de 2025 Protocolado em 17 de dez. de 2025Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Alienado (D)27——0Direta (D) Não
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir documento 0001193125-25-322639 Lido do XML do documento Contestar esta linha
16 de dez. de 2025 Protocolado em 17 de dez. de 2025CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Alienado (D)360——0Direta (D) Não
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir documento 0001193125-25-322644 Lido do XML do documento Contestar esta linha
16 de dez. de 2025 Protocolado em 17 de dez. de 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Alienado (D)15.509——0Direta (D) Não
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir documento 0001193125-25-322637 Lido do XML do documento Contestar esta linha
16 de dez. de 2025 Protocolado em 17 de dez. de 2025Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
Alienado (D)11.815——0Direta (D) Não
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
Abrir documento 0001193125-25-322640 Lido do XML do documento Contestar esta linha

Detentores institucionais (Formulário 13F)

Nenhuma posição do Formulário 13F está ligada a este emissor no repositório. Um detentor ainda não vinculado ou que ainda não entregou está ausente, não em zero.

Detentores de 5 % (Schedules 13D e 13G)

Aqui são lidos os schedules entregues no formato estruturado da SEC (desde o fim de 2024). Os anteriores são texto livre e não são lidos.

Detentores de 5 %, evento mais recente primeiro, conforme entregue
DetentorPercentual da classeAções detidasData do eventoFormulárioFonte
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00,0012/17/2025 Protocolado em 19 de dez. de 2025SCHEDULE 13D/AEmenda 5Abrir documento 0001104659-25-123157 Contestar esta linha
Harkey Wilmot B. Common Stock, par value $0.0001 per share00,0012/17/2025 Protocolado em 19 de dez. de 2025SCHEDULE 13D/AEmenda 5Abrir documento 0001104659-25-123157 Contestar esta linha
Mack Daniel Common Stock, par value $0.0001 per share00,0012/17/2025 Protocolado em 19 de dez. de 2025SCHEDULE 13D/AEmenda 5Abrir documento 0001104659-25-123157 Contestar esta linha
Morgan Stanley Common Stock0.03111/30/2025 Protocolado em 5 de dez. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0000895421-25-000595 Contestar esta linha
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 Protocolado em 5 de dez. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0000895421-25-000595 Contestar esta linha
Klein Roger M. Common Stock, par value $0.0001 per share10.5163.000,0011/04/2025 Protocolado em 12 de nov. de 2025SCHEDULE 13DAbrir documento 0001651175-25-000007 Contestar esta linha
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129.000,0011/04/2025 Protocolado em 12 de nov. de 2025SCHEDULE 13DAbrir documento 0001651175-25-000007 Contestar esta linha
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Protocolado em 4 de nov. de 2025SCHEDULE 13D/AEmenda 4Abrir documento 0001104659-25-106048 Contestar esta linha
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Protocolado em 4 de nov. de 2025SCHEDULE 13D/AEmenda 4Abrir documento 0001104659-25-106048 Contestar esta linha
Mack Daniel Common Stock, par value $0.0001 per share15.99268.431,0011/03/2025 Protocolado em 4 de nov. de 2025SCHEDULE 13D/AEmenda 4Abrir documento 0001104659-25-106048 Contestar esta linha
Morgan Stanley Common Stock10.5163.71808/31/2025 Protocolado em 8 de set. de 2025SCHEDULE 13GAbrir documento 0000895421-25-000528 Contestar esta linha
Morgan Stanley Smith Barney LLC Common Stock10.5163.71808/31/2025 Protocolado em 8 de set. de 2025SCHEDULE 13GAbrir documento 0000895421-25-000528 Contestar esta linha

O percentual é da classe indicada no documento, como declarado pelo detentor. Os membros de um grupo informam cada um as ações do grupo, por isso as linhas não se somam.

O que foi lido

2.092.408 documentos lidos, de 14 de jun. de 2004 a 13 de nov. de 2026: Formulários 3, 3/A, 4, 4/A, 5, 5/A.

Alguns anos podem estar incompletos enquanto o arquivo ainda é lido. Um ano com poucos documentos aqui não afirma que poucos foram entregues.

Documentos lidos, por ano de entrega
Ano de entregaDocumentos lidos
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202240.015
2023199.811
2024185.386
2025235.520
2026254.737

Os documentos anteriores à exigência de XML pela SEC são listados, mas não extraídos.

Voltar para Evoke Pharma Inc